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The number of compensated occupational cancers in Germany is
still rising (Butz, 1996). The most frequent occupational cancers
are lung carcinomas (45.9%) and mesotheliomas of the pleura,
peritoneum and pericardium (37.5%). Currently, approximately
two-thirds (68.6%) of all occupational cancers eligible for
compensation are due to asbestos fibres. The second most
common occupationally derived lung cancers (10.5%) are due to
ionizing radiation, especially that caused by radon and its decay
products. Aromatic amines account for 6.4% and polycyclic
hydrocarbons 3.3% of cancer cases originating in the workplace
(Butz, 1996). Because lung cancer occupies such a prominent
place on the list of causes of cancer deaths, especially among men
in the Western industrialized world, early detection of these
tumours should be a major focus of interest. Improved secondary
prevention by early detection may be a solution. To this end,
special laboratory procedures employing bio-markers or bio-
indicators are available.
Cancer is a result of a number of genetic alterations that disturb
normal, controlled cell growth and differentiation (Harris, 1997).
Proto-oncogenes and tumour suppressor genes and their products
are key components of a cellular regulatory mechanism. The
tumour suppressor gene product p53 and the epidermal growth
factor receptor (EGF-R), an oncogene product, are associated with
lung cancer pathogenesis and are likely to play a key role in the
development of cancer (Harris and Hollstein, 1993). Since certain
carcinogenic substances are known to cause particular mutations
on certain genes (Vähäkangens et al, 1994), clues about the iden-
tity of these carcinogens should come from determination of onco-
gene and tumour suppressor gene products. In accordance with an
elevated intracellular concentration, the proteins mentioned above
have also been detected in the serum of tumour patients, some
even before clinical manifestation of cancer (Brandt-Rauf et al,
1992; Luo et al, 1994). Autoimmune antibodies against p53
(anti-p53 AB) can also be detected in the serum of cancer patients
(Harris and Hollstein, 1993). In light of the greater stability of
antibodies as compared with the p53 protein product, the detection
of anti-p53 AB might be a more efficient screening method.
In the present investigation, the suitability of EGF-R, p53
protein, or p53 autoimmune antibodies as bio-markers or bio-
indicators detectable in serum was assessed as a method of early
detection of malignant diseases of the lung induced by asbestos or
radon and its products. Furthermore, the possible influence of
non-occupational factors such as cigarette smoking was examined.
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Summary The oncogene product epidermal growth factor receptor (EGF-R), the tumour suppressor gene product p53 and anti-p53
antibodies are detectable in the serum of certain cancer patients. Increased levels of some of these products were reported in lung cancer
patients after occupational asbestos exposure and after exposure to polycyclic aromatic hydrocarbons or vinylchloride. In the first step, this
study investigated the possible diagnostic value of serum EGF-R, p53-protein and anti-p53 antibodies, measured by an enzyme-linked
immunosorbent assay, in lung tumour patients. In addition to being investigated on a molecular epidemiological basis, these parameters were
examined as biomarkers of carcinogenesis, especially with regard to asbestos incorporation effects or of radon-induced lung cancers. Also, a
possible effect of cigarette smoking and age dependence were studied. A total of 116 male patients with lung or pleural tumours were
examined. The histological classification was four small-cell cancers, six large-cell cancers, 32 adenocarcinomas, 47 squamous carcinomas,
12 mixed lung carcinomas, five diffuse malignant mesotheliomas and ten lung metastasis of extrapulmonary tumours. Twenty-two lung
cancers and all mesotheliomas were related to asbestos, 22 lung cancers were related to ionizing radiation and 61 patients had cigarette
smoke-related lung cancer. Besides these patients 50 male patients with non-malignant lung or pleural diseases were included; of the latter
eight subjects suffered from asbestosis. Controls were 129 male subjects without any lung disease. No significantly elevated or decreased
serum values for p53 protein, EGF-R, or anti-p53 antibodies as a function of histological tumour type, age, or degree and type of exposure
(asbestos, smoking, ionizing radiation) could be found. The utility of p53-protein, EGF-R and anti-p53 antibodies as routine biomarkers for
screening occupationally derived lung cancers is limited.
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Disease status and histological tumour type of the
subjects
Within the framework of this multi-centre, molecular biology-
based project, 129 male subjects (65.3 ± 5.4 years of age) without
lung disease (Controls), 50 male patients (53.2 ± 13.2 years) with
non-malignant lung/pleural disease (NMLD) and 116 male
patients (63.3 ± 9.3 years) with lung or pleural tumours (Tumour-
Patients) were examined. Among the patients with tumours were
five with diffuse malignant pleuralmesothelioma (DMM) (61.6 ±
8.8 years) and ten with lung metastases of extrapulmonary primary
tumours (55.0 ± 11.4 years). Histological classification of the lung
carcinoma cases yielded four small-cell cancers (64.3 ± 7.6 years),
six large-cell cancers (69.0 ± 9.0 years), 32 adenocarcinomas
(62.7 ± 8.0 years), 47 squamous (64.8 ± 8.6) and 12 mixed or
non-classifiable bronchial carcinomas (62.0 ± 12.7 years). Of the
patients with NMLD, 26 had an acute inflammatory lung/pleural
infection (49.4 ± 13.8 years) and 24 suffered from interstitial lung
fibrosis (57.3 ± 11.7 years). The health status of each subject was
confirmed in a clinical examination that included X-rays. All
patients underwent bronchoscopy.
Type of exposure (asbestos, ionizing radiation,
polycyclic aromatic hydrocarbons)
To allow further discrimination between different kinds of expo-
sure, several groups of tumour patients or patients suffering from
fibrosis were created in a second evaluation step and compared to
a non-exposed control group.
The tumour patients were as follows: 22 patients (64.5 ± 9.4
years) with asbestos-related lung cancer as defined in the list of
occupational diseases (criteria for diagnosis: see DeVuyst, 1997),
five patients (61.6 ± 6.8 years) with diffuse malignant mesothe-
liomas caused by asbestos dust, 61 patients (63.1 ± 9.0 years) with
cigarette smoke-related lung cancer, i.e. lung cancer in cigarette
smokers with no relevant exposure to other known occupational
lung carcinogens and 21 former uranium miners of SDAG Wismut
(67.5 ± 5.9 years) with lung cancer related to ionizing radiation
(radon and its decay products) (criteria for diagnosis: see
Eigenwillig, 1997).
The patients with fibrosis included eight subjects (64.5 ± 6.8
years) with asbestosis (criteria for diagnosis: see Parker, 1997) and
16 subjects (53.8 ± 12.1 years) suffering from lung interstitial
fibrosis without any relevant asbestos exposure.
A non-exposed control group (n = 13, 58.4 ± 7.0 years old) was
defined as healthy subjects without exposure to carcinogenic (or
fibrogenic) agents at the work place mentioned above, i.e. never
having smoked or knowingly been exposed to asbestos dust or
ionizing radiation.
Age and smoking habits
Because of different ages and smoking habits in the various patient
groups, a possible dependence of the p53 protein and EGF-R
levels was examined. For the age comparison, the results for all
serum samples (n = 295) were evaluated. To examine the influence
on smoking habits all sera of former and current smokers were
analysed (n = 238).
Serum specimens
All sera were frozen following venipuncture, centrifuged and
stored in liquid nitrogen until analysis. All analyses were
performed in duplicate. p53 protein, anti-p53 antibodies and EGF-
R were measured in serum by commercially available enzyme-
linked immunosorbent assay (ELISA) kits (Oncogene Science,
supplied by Dianova, Hamburg, Germany) according to the manu-
facturer’s instructions.
p53
The serum dilution was 1:5. The assay uses anti-p53 antibodies
from rabbits as reporter antibodies, which react with mutant and
wild-type human p53. The minimum concentration detectable was
reportedly 10 pg ml–1.
Anti-p53 antibodies
The serum dilution was 1:100. The assay was calibrated by three
standards of various anti-p53 antibody concentrations. Samples
were qualitatively judged positive or negative. A reaction was
judged positive when the absorbance reading was equal to or
greater than the absorbance of the low positive control value
obtained with the ELISA kits.
EGF-R
The serum dilution was 1:4. The lower detection limit was 5 fmol
ml–1, as reported by the manufacturer. For all tests, absorbance was
measured in each well by a spectrophotometric microplate reader
(Bibbi Dunn, Asbach, Germany).
Statistical analysis
Data were statistically analysed with SAS for Windows 6.08
(SAS, Cary, NC, USA). The Shapiro–Wilk test was used first to
check for a normal distribution of values. Because of non-normal
distribution in all groups, statistical comparisons between all
groups were investigated by the non-parametric Wilcoxon test. A
P-value of 0.05 or less was considered as statistically significant.
RESULTS
Comparative evaluation with respect to disease status
and histological tumour type
The results of the measurement of p53 protein and EGF-R in
serum showing minimum, maximum, median and mean values are
given in Table 1. There were no significant differences in p53
protein or EGF-R concentrations in serum from patients with
tumours as compared with patients having non-malignant lung
disease or healthy control subjects.
In order to evaluate the suitability of these parameters as bio-
markers for particular diagnostic types of malignant lung/pleural
diseases, a possible influence of the histological tumour type on
the expression of the bio-markers was examined. A summary of
the values for p53 protein and EGF-R in serum as a function of
histological tumour type are listed in Table 1. When analysed as a
function of histological tumour type, there were no significant
differences in serum values for both p53 protein and EGF-R,
possibly owing to the small number of patients in some of the
groups.
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was detected in 43 (= 14.6%) out of a total of 295 serum samples
(Table 1). Antibodies against the p53 gene product were found in
sera from half of the patients with small-cell carcinoma, which
represents the highest prevalence. No anti-p53 AB was detected in
sera from patients with large-cell bronchial carcinoma or diffuse
malignant pleuramesothelioma. A number of serum samples from
healthy subjects and patients with non-malignant lung disorders
also contained anti-p53-AB (12% in each group). Taken together,
these data showed no significant differences between the different
groups.
Comparative evaluation with respect to type of
exposure
The central question of this study was the suitability of p53
protein, EGF-R and anti-p53 AB as markers for diseases due to
asbestos fibres, ionizing radiation, or smoking. Table 2 shows
minimum, maximum, median and mean values for both p53
protein and EGF-R, as well as the occurrence of anti-p53 AB and
the results of biometrical tests for significance of data gathered
from various patient groups, including non-smoking, healthy
control subjects who had not been exposed to asbestos or ionizing
radiation in the workplace. The tests applied showed no significant
differences between all groups concerning the concentration of
either p53 protein, EGF-R or the occurrence of anti-p53 antibodies
in serum.
It must be taken into account that disorders arising from
asbestos exposure cannot be differentiated clinically or pathologi-
cally from tumours, respectively, interstitial fibrosis originating
from other causes. Our data also do not allow for this discrimina-
tion. In addition, lung cancer in former uranium miners caused
by radon and its decay products had no effect on the analysed
parameters.
Age dependence of p53 protein and EGF-R
concentrations in serum
Because of different ages in the various patient groups, a possible
dependence on age for levels of p53 protein and EGF-R was
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Table 1 p53 and EGF-R concentrations in serum and detection of anti-p53 antibodies in healthy individuals and in patients with malignant or non-malignant
lung disorders
Subjects: histology of cancer
p53 (pg ml–1) EGF-R (fmol ml–1) Anti-p53 antibodies
n Min. Max. Med. Mean P Min. Max. Med Mean P Negative Positive Positive P
(n)( n) results (%)
Controls 129 73 5153 469 579 – 18 67 36 37 – 114 15 12 –
NMLD 50 157 2127 514 560 0.85 21 156 39 41 0.19 44 6 12 0.85
Tumour-Patients 116 86 2628 541 578 0.25 18 138 37 39 0.25 94 22 19 0.15
Small-cell LC 4 86 1069 530 554 0.97 30 49 35 37 0.97 2 2 50 0.08
Large-cell LC 6 243 648 479 478 0.78 27 39 33 33 0.27 6 0 0 1.00
Adenocarcinoma LC 32 194 1531 521 600 0.28 18 56 37 38 0.41 26 6 19 0.38
Squamous LC 47 117 2628 574 611 0.13 20 69 38 38 0.43 36 11 23 0.09
Mixed, non-classificable LC 12 212 1120 408 550 0.93 26 138 36 44 0.73 10 2 17 0.64
DMM 5 400 684 508 528 0.65 28 58 36 41 0.49 5 0 0 1.00
Lung-metastasis of extrapulmonary 10 201 772 455 461 0.40 24 60 40 42 0.11 9 1 10 1.00
tumours
DMM, diffuse malignant mesothelioma; NMLD, non-malignant lung diseases, i.e. fibrosis (n = 24) or inflammatory diseases (n = 26); LC, Lung cancer;
Min, minimum; Max, maximum; Med, median.
Table 2 p53 and EGF-R concentrations in serum and detectable anti-p53 antibodies as a function of various occupational or environmental factors
p53 (pg ml–1) EGF-R (fmol ml–1) Anti-p53 antibodies




Non-smokers without asbestos or 13 231 874 527 541 – 25 44 35 35 – 11 2 15 –
ionizing radiation exposure
Tumour-patients
Mesothelioma due to asbestos 5 400 684 508 528 0.80 28 58 36 41 0.35 5 0 0 0.5
LC due to asbestos 22 117 2628 656 674 0.44 27 138 39 44 0.09 19 3 14 0.63
LC due to ionizing radiation 21 211 1326 564 632 0.48 23 50 37 37 0.47 18 3 14 0.65
LC due to smoking 61 86 1531 491 547 0.73 18 65 37 37 0.62 45 16 26 0.33
Patients with lung fibrosis
Asbestosis 8 283 2127 476 666 0.71 25 52 35 37 0.66 7 1 13 0.68
Lung fibrosis not due to asbestos 16 293 1400 542 642 0.91 22 156 33 52 0.52 13 3 19 0.60
LC, lung cancer; Min, minimum; Max; maximum; Med, median. examined. For this comparison, the results for all serum samples
(n = 295) were evaluated. There was no dependence on age for all
three parameters tested. As can be seen in Figure 1 the highest
value for p53 (5153 pg ml–1) was obtained for a 75-year-old
ex-smoker. Clinical examination of this patient revealed no
obvious disorders. The highest concentrations of EGF-R in serum
were measured for a non-smoking 53-year-old patient with idio-
pathic interstitial lung fibrosis (156 fmol ml–1) and a 77-year-old
patient (ex-smoker with 41 cumulative pack-years) with asbestos-
induced lung cancer (138 fmol ml–1) (Figure 2).
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Figure 1 p53 protein in serum as a function of age. p53 concentrations in sera of all paticipants (n = 295) were measured as described in Methods. The linear
regression is shown. The calculated correlation coefficient is r = 0.06
Figure 2 EGF-R in serum as a function of age. EGF-R concentrations in sera of all participants (n = 295) were measured as described in Methods. The linear
regression is shown. The calculated correlation coefficient is r = 0.05Dependence of p53 protein and EGF-R concentration
on smoking
The study population contained a total of 238 smokers or
ex-smokers. To examine the dose–response relationship, the
concentrations of p53 protein and EGF-R were plotted as a
function of the cumulative time of exposure taken from patients’
reported history of pack-years (PY). One PY is the equivalent of
smoking about 20 cigarettes per day over the time period of 1 year.
The results of this comparison are shown in Figure 3 and 4. There
was no significant correlation between the cumulative dose of
cigarette smoking (smoking index) and concentrations of the two
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Figure 3 p53 protein in serum as a function of cigarette consumption. p53 concentrations in sera of all individuals who had ever smoked (n = 238) were
measured as described in Methods (PY = pack years). The linear regression is shown. The calculated correlation coefficient is r = 0.0
Figure 4 EGF-R in serum as a function of cigarette consumption. EGF-R concentrations in sera of all individuals who had ever smoked (n = 238) were






















































































)bio-markers in serum. This is also true for anti-p53 antibodies
(data not shown).
DISCUSSION
Oncogene and tumour suppressor gene products have been linked
to the occurrence of certain cancers (for overview see Barker and
Vinson, 1990; Sugimura et al, 1991; Wynford-Thomas, 1991;
Micelli et al, 1992; Burkhart, 1994; Lahdeaho et al, 1994; Trumper
et al, 1994). The ubiquity and high frequency of p53 mutations in
human malignancies is consistent with p53 protein being an
important tumour suppressor gene product. Mutations in the p53
gene represent one of the most common genetic aberrations in
lung cancer (Brambilla et al, 1993; Minna, 1993; Kaye et al,
1995). For example, mutations appear in 70–100% of small-cell
carcinomas and in 40–60% of non-small-cell tumours (Minna,
1993; Kaye et al, 1995). The occurrence of p53 mutations has even
been associated with a shortened patient survival (Horio et al,
1994), although this finding could not be verified by other authors
(Van Zandwijk et al, 1995). Certain p53 mutations appeared to be
specific for radon-associated lung cancer (Taylor et al, 1994). The
protein product of the p53 gene represents an important tumour
suppressor protein that is also detectable in serum (Fontanini et al,
1994). In the serum of 42% of lung cancer patients, both the wild-
type and mutant forms of p53 were detected (Fontanini et al,
1994). Significantly higher concentrations of p53 protein were
found in the serum of patients with advanced tumours.
A significant overexpression of p53 protein in sera has been
reported in individuals after asbestos exposure than in people
without such exposure (Nuorva et al, 1994). Lou and co-workers
(1994) determined a higher mean concentration of p53 protein in
sera of patients with asbestos-derived lung cancer as compared
with sera from lung carcinoma patients who had no occupational
asbestos exposure or with control sera from patients without
cancer. This difference, however, did not prove to be significant.
Husgafvel-Pursiainen et al (1997) mentioned that there was a
statistically significant difference in the rate of p53 seropositivity
between cancers following asbestos and silica exposure (36%) and
the non-cancer controls (6%).
High levels of serum pantropic p53 proteins have also been
associated with high risk for lung cancer in workers after a long
duration of exposure to chromium compounds (Hanaoka et al,
1997). The authors suggested that this would be an early effect
marker and a possible indicator of cancer risk.
Data in the literature concerning lung cancer and asbestos-asso-
ciated diseases could not be corroborated in our investigation of
sera from patients or exposed subjects (Tables 1 and 2). The
measured values for p53 protein in serum from our patient groups
are in the range of values reported in the literature (Fontanini et al,
1994; Luo et al, 1994), but there were no significant differences in
serum levels between the groups we examined. There were also no
differences as a function of histological tumour type, possibly
owing to the scatter of the data.
No correlation was found between p53 protein concentration in
serum and the occurrence of either asbestos-associated lung
diseases or Schneeberg lung cancer (Table 2). Based on these
results, the presence of p53 protein in serum does not appear to be
a useful bio-marker for asbestos- or radon-induced lung cancer.
Exposure to polycyclic aromatic hydrocarbons as a result of ciga-
rette smoking also did not have an influence on the level of p53
protein in serum. The results of our investigation of p53 protein in
serum based on the commercially available ELISA does not allow
any aetiological differentiation of the origin of cancer.
In agreement with Segawa et al (1997), the levels of p53 protein
in sera were not correlated with age and smoking index (Figures 1
and 3). The measurement of p53 protein serum levels was not
found to be clinically useful neither for detection of small-cell
lung cancer nor for detection of other histological types of lung
cancer (Table 1).
Furthermore, Levesque et al (1996) could not confirm the pres-
ence of p53 protein in the serum of patients with lung cancer. In
addition, these authors discussed possible analytical difficulties
with the measurement of p53 protein in biological fluids. Thus,
interference by heterophilic antibodies could nullify the results.
They concluded that the detection of p53 protein in sera of lung
cancer patients had to be interpreted with caution.
Besides the p53 protein, antibodies against the p53 protein have
been detected in a large proportion of lung cancer patients (Harris
and Hollstein, 1993; Winter et al, 1993; Angelopoulou et al, 1994;
Mudenda et al, 1994; Preudhomme et al, 1994). The prevalence of
anti-p53 antibodies in serum from lung cancer patients is reported
between 15% (Wild et al, 1995) and about 30% (Schlichtholz et al,
1994; Lubin et al, 1995) and was also dependent on histological
tumour type (Table 3).
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Table 3 Anti-p53 antibody determination as a function of histological tumour type
First author, year Total Histological tumour type
LC
Small-cell LC Non-small-cell LC
Total Large-cell Adeno Squamous Mixed
n % n % n % n % n % n % n %
Winter, 1992 6/46 13 4/40 10 2/6 33 NA – NA – NA – NA –
Winter, 1993 24/40 24 21/36 58 3/4 75 NA – NA – NA – NA –
Schlichtholz, 1994 10/42 24 4/9 44 6/33 18 2/5 40 2/10 20 2/18 11 NA –
Wild, 1995 16/136 12 1/7 14 15/129 12 0/8 0 3/49 6 11/70 16 1/2 50
Trivers, 1995 2/15 13 NA – NA – NA – NA – NA – NA –
Rosenfeld, 1997 27/170 16 27/170 16 NA – NA – NA – NA – NA –
This study 21/101 21 2/4 50 19/97 20 0/6 0 6/32 19 11/47 23 2/12 17
NA, not available; LC, Lung cancers.Antibodies to p53 protein have never been detected in the serum
of healthy subjects (Rosenfeld et al, 1997). In some cases, anti-p53
antibodies were found in the serum of cancer patients before clin-
ical manifestation of disease (Schlichtholz et al, 1994; Lubin et al,
1995; Trivers et al, 1995). Trivers and co-workers determined the
presence of anti-p53 antibodies 4 months, in particular even 11.3
and 10.8 years, before diagnosis of cancer. Individuals with
detectable anti-p53 antibodies had an improved survival compared
with patients without these antibodies (Winter et al, 1993).
No significant differences were found between patients with
malignant or benign lung disorders and healthy control subjects in
our investigation of anti-p53 antibodies in serum (Table 1). There
was also no dependence on histological tumour type. Also the type
of exposure (asbestos, cigarette smoke, or radon and its decay
products) also did not appear to have any influence on this para-
meter. There were no significant differences in the prevalence of
anti-p53 antibodies between the various patient groups or between
patients and healthy controls. It should be noted, however, that 15
(12%) healthy subjects and six (12%) patients with non-malignant
disorders showed elevated levels of anti-p53 antibodies in serum.
The predictive value of anti-p53 antibodies awaits the results of a
planned follow-up.
Another oncogene product of interest is the EGF-R, which is the
product of the erb B1 gene. An immunohistochemical overexpres-
sion is a common trait of human tumours, which has been
observed for non-small-cell bronchial carcinomas (squamous cell
carcinomas or adenocarcinomas) (Haeder et al, 1988; Sozi et al,
1991; Birrer and Brown, 1992; Pavelic et al, 1993; Rusch et al,
1993; Weissfeld et al, 1994; Brandt-Rauf et al, 1995; Sorscher
et al, 1995). EGF-R could also be detected in serum. In our study,
EGF-R levels were not elevated in patients with lung cancer or
mesothelioma (Table 1). There were also no differences in EGF-R
serum concentrations as a function of histological tumour type or
age (Figure 2). Thus, the observations of Ambs et al (1989)
concerning patients with kidney tumours or of Choi et al (1997)
with stomach carcinoma patients could not be confirmed for lung
cancer patients.
For causal analysis the reports from Partanen et al (1994a,
1994b) and Brandt-Rauf et al (1995) are important. Partanen and
co-workers examined sera from 110 asbestosis patients for the
appearance of EGF-R. Of these patients, 27 eventually developed
bronchial carcinoma and three others pleuralmesothelioma. The
EGF-R values in serum from these patients were significantly
higher than those of control patients without asbestos exposure.
Brandt-Rauf et al (1995) found elevated concentrations of EGF-R
in seven out of 38 pneumokoniosis patients, among them three
with lung carcinoma and one with mesothelioma.
A statistically significant overexpression of EGF-R in serum,
however, could not be demonstrated in any group in our investiga-
tion. Based on our results, EGF-R cannot be viewed as a marker
for early effects of occupational diseases due to asbestos or for
radon-induced lung cancer.
CONCLUSIONS
In the literature there is evidence supporting the utility of the
tumour markers examined in this study with regards to the effects
of certain carcinogenic substances found in the workplace. In
contrast, our investigation found no significantly elevated or
decreased serum values for p53 protein, EGF-R, or anti-p53 anti-
bodies as a function of tumour type, histology, age, or degree and
type of exposure (asbestos, smoking, ionizing radiation). Based on
these results, routine use of the bio-markers examined as deter-
minants of occupationally derived lung carcinomas cannot be
recommended. Since anti-p53 antibodies were also found in the
sera of subjects without clinical evidence of cancer, the predictive
value of this potential bio-marker should only be evaluated after
long-term follow-up.
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